Bone mineral changes during pregnancy: a cross-sectional study

Background: Changes in bone mineral density during pregnancy are not widely studied because of the risk of radiation hazard to the fetus. But newer technology like DEXA has made it possible to measure bone density accurately with low dose radiations which are safe even during pregnancy. The aim of this study was to evaluate the changes in maternal bone turnover markers and bone mineral content at forearm during pregnancy.Methods: A total of 32 pregnant women with singleton pregnancy of more than thirty five weeks gestational age and thirty non-pregnant, non-lactating women as controls were recruited. Baseline blood investigations, serum calcium, serum alkaline phosphatase and DEXA of the forearm at ultra-distal, mid radius and proximal 1/3rd of radius were done at the time of recruitment into the study.Results: Bone mineral density of forearm of pregnancy group was compared with non-pregnant, non-lactating control group to see the effect of pregnancy. Bone turnover markers like serum calcium and serum ALP were also compared among pregnancy group and controls. The mean bone mineral density of controls at ultra-distal radius was 0.437±0.058g/cm2, while in pregnant women it was 0.431±0.58g/cm2 that was not statistically significant. Bone mineral density at mid radius in control was 0.599±0.051g/cm2 and in pregnant women it was 0.597±0.048 g/cm2 with no significant difference. BMD at proximal 1/3rd radius in controls was 0.670±0.36 g/cm2 as compared to pregnant women where it was 0.660±0.036 g/cm2 without any statistical significance. Total BMD at forearm in control and pregnant women was 0.586±0.035 and 0.582±0.036 respectively and again there was no statistically significant difference.Conclusions: There is no significant impact of pregnancy on bone mineral density of forearm. Although more bone areas need to be investigated for the further confirmation.

Download Full-text

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

Journal of Osteoporosis ◽

10.1155/2016/8738959 ◽

2016 ◽

Vol 2016 ◽

pp. 1-6 ◽

Cited By ~ 4

Author(s):

A. Sánchez ◽

L. R. Brun ◽

H. Salerni ◽

P. R. Costanzo ◽

D. González ◽

...

Keyword(s):

Bone Mineral Density ◽

Bone Turnover ◽

Postmenopausal Women ◽

Bone Mineral ◽

Bone Turnover Markers ◽

Control Group ◽

Bone Resorption Marker ◽

Similar Response ◽

Mineral Density ◽

Turnover Markers

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab.Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.

Download Full-text

Effect of hypercortisolism on bone mineral density and bone metabolism: A potential protective effect of adrenocorticotropic hormone in patients with Cushing’s disease

Journal of International Medical Research ◽

10.1177/0300060517725660 ◽

2017 ◽

Vol 46 (1) ◽

pp. 492-503 ◽

Cited By ~ 9

Author(s):

Weihong Guo ◽

Fengao Li ◽

Chonggui Zhu ◽

Baoping Wang ◽

Kunling Wang ◽

...

Keyword(s):

Bone Mineral Density ◽

Bone Turnover ◽

Bone Metabolism ◽

Bone Mineral ◽

Bone Turnover Markers ◽

Adrenocorticotropic Hormone ◽

Cushing's Disease ◽

Control Group ◽

Mineral Density ◽

Turnover Markers

Objective To investigate the effects of Cushing’s disease (CD) and adrenal-dependent Cushing’s syndrome (ACS) on bone mineral density (BMD) and bone metabolism. Methods Data were retrospectively collected for 55 patients with hypercortisolism (CD, n = 34; ACS n = 21) from January 1997 to June 2014. BMD was examined in all patients, and bone turnover markers were tested in some patients. Healthy controls (n = 18) were also recruited. Results The lumbar spine and femoral neck BMD were significantly lower in the ACS and CD groups than in the control group. Lumbar BMD was significantly lower in the ACS than CD group. The collagen breakdown product (CTX) concentrations were significantly higher while the osteocalcin and procollagen type I N-terminal propeptide (PINP) concentrations were significantly lower in the ACS and CD groups than in the control group. The PINP concentration was significantly lower while the CTX concentration was significantly higher in the ACS than CD group. In the CD group only, lumbar BMD and serum adrenocorticotropic hormone had a significant positive correlation. Conclusions Bone turnover markers indicated suppressed osteoblast and enhanced osteoclast activities. PINP and CTX changes might indicate bone mass deterioration. Adrenocorticotropic hormone might be protective for lumbar BMD in patients with CD.

Download Full-text